Cellectis SA (NASDAQ:CLLS)

9.24
Delayed Data
As of 4:00pm ET
 +1.17 / +14.50%
Today’s Change
7.80
Today|||52-Week Range
34.71
-65.85%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$391.0M

Company Description

Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. It offers Gene editing and Immuno-oncology. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Contact Information

Cellectis SA
8, rue de la Croix Jarry
Paris Ile-de-france 75013
P:(318) 169-1600
Investor Relations:

Employees

Shareholders

Mutual fund holders21.22%
Other institutional14.67%
Individual stakeholders--

Top Executives

André ChoulikaChief Executive Officer & Director
Eric DutangChief Financial Officer
Philippe DuchateauChief Scientific Officer
Francisco J. EstevaVice President-Clinical Development
Carrie BrownsteinChief Medical Officer